BOT - Anything but charting, page-3690

Probably be planned once some more guidance on SB timelines come to light..

SB is the key to all of this as it is a revenue generating product.

Once the market realises that Botanix is actually making revenue and will make significant revenue from SB globally, then the price will quickly adjust north.

Revenue from SB is the key to all of this as we know the acne programme and the antibiotic programme's are first class. We forget the strength of BTX1801 on both gram positive and gram negative bacteria. It's actually incredible what has been achieved there. FDA has given fast track approval also.

The acne results from phase 2 in Australia were also outstanding. We also know why the US trial side of the arm failed. Lessons have been learned.

You need money to advance everything unfortunately.. The acquisition of SB in hindsight was a stroke of genius. Without that we would have been continued to be diluted into oblivion as shareholders.

An extremely exciting year ahead.